ResMed (NYSE: RMD) divests MatrixCare for $490M, plans capital returns
Rhea-AI Filing Summary
ResMed is reshaping its portfolio by agreeing to sell its MatrixCare software business to Frazier Healthcare Partners for $490 million in cash, with closing expected in the first quarter of fiscal 2027, subject to regulatory approvals and customary conditions. MatrixCare generated about $220 million of revenue and $55 million of non-GAAP operating profit in fiscal 2026.
ResMed plans to use net proceeds to return capital to shareholders, including via an accelerated share repurchase program, and for general corporate purposes. Transition services agreements are expected to largely offset first-year stranded costs. The company also notes its Noctrix acquisition should add roughly $30 million of revenue in fiscal 2027 but reduce non-GAAP diluted EPS by about $0.20, while it reiterates its fiscal 2026 outlook and targets high single-digit revenue growth with operating leverage in its Residential Care Software segment in fiscal 2027.
Positive
- ResMed secures $490 million in all-cash consideration for the MatrixCare divestiture, supporting capital returns such as an accelerated share repurchase and funding for core sleep and connected care growth initiatives.
- MatrixCare delivered approximately $220 million of revenue and $55 million of non-GAAP operating profit in fiscal 2026, and the sale is positioned as aligning the portfolio with ResMed’s 2030 strategy focus areas.
Negative
- The recently completed Noctrix acquisition is expected to reduce fiscal 2027 non-GAAP diluted EPS by approximately $0.20, introducing a near-term earnings headwind despite its anticipated revenue contribution of about $30 million.
Insights
ResMed sells MatrixCare for $490M cash, funds buybacks, and flags a modest EPS headwind from Noctrix in fiscal 2027.
The agreement to sell MatrixCare for $490 million in cash sheds a non-core software asset that produced about $220 million of revenue and $55 million of non-GAAP operating profit in fiscal 2026. Management links the move to its 2030 strategy, emphasizing focus on sleep, breathing, and connected home-based care.
Net proceeds are earmarked for capital returns, including an accelerated share repurchase, and general corporate purposes, while transition services agreements are intended to offset first-year stranded costs. Separately, the Noctrix acquisition is expected to add around $30 million of revenue but cut non-GAAP diluted EPS by about $0.20 in fiscal 2027, creating a near-term earnings drag. The company reiterates its fiscal 2026 outlook and signals high single-digit growth with operating leverage in its Residential Care Software segment for fiscal 2027, with more detailed guidance coming on August 6, 2026.
8-K Event Classification
Key Figures
Key Terms
non-GAAP operating profit financial
transition services agreements financial
stranded costs financial
Residential Care Software (RCS) segment financial
FAQ
What transaction did ResMed (RMD) announce regarding its MatrixCare business?
How large is MatrixCare within ResMed (RMD) based on recent results?
When is the MatrixCare sale expected to close for ResMed (RMD)?
How will ResMed (RMD) use the $490 million from the MatrixCare sale?
What financial impact will the Noctrix acquisition have on ResMed (RMD) in fiscal 2027?
What growth outlook did ResMed (RMD) give for its Residential Care Software segment?
Is ResMed (RMD) changing its fiscal 2026 financial outlook after the MatrixCare deal?
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Under Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
| Item 2.02. | Results of Operations and Financial Condition. |
On July 7, 2026, ResMed Inc. (the “Company” or “Resmed”) issued a press release announcing that on June 30, 2026 it entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused exclusively on healthcare. The $490 million all-cash transaction, subject to certain closing adjustments, is expected to close during the first quarter of Resmed’s fiscal year 2027, subject to required regulatory approvals and customary closing conditions.
Resmed intends to use net proceeds from the transaction to return capital to shareholders, including through an accelerated share repurchase (ASR) program, and for general corporate purposes.
Resmed and Frazier Healthcare Partners expect to enter into transition services agreements (“TSAs”) to facilitate continuity across systems, processes, tools, and day-to-day operations. These TSAs will largely offset stranded costs in the first-year post-closing. Resmed intends to mitigate and eliminate any remaining stranded costs over time.
Based on preliminary financial results for the full fiscal year 2026, the MatrixCare business represented approximately $220 million of revenue and approximately $55 million of non-GAAP operating profit. In addition to the MatrixCare business-related financial considerations, Resmed’s recently completed Noctrix acquisition is expected to contribute approximately $30 million of revenue and reduce non-GAAP diluted EPS by approximately $0.20 in fiscal year 2027.
Resmed continues to expect its Residential Care Software (RCS) segment to accelerate to high single digit percentage year-over-year revenue growth, along with operating leverage, in fiscal year 2027. Resmed will provide its full fiscal year 2027 outlook during its fourth quarter fiscal year 2026 earnings call on August 6, 2026.
Resmed reiterates its full year fiscal year 2026 outlook for non-GAAP gross margin, non-GAAP SG&A as a percentage of revenue, R&D as a percentage of revenue, and non-GAAP tax rate, as provided on Resmed’s third quarter fiscal year 2026 earnings call on April 30, 2026. Resmed is also reiterating its fourth quarter fiscal year 2026 outlook for net interest income and planned share repurchases, as provided on Resmed’s third quarter fiscal year 2026 earnings call on April 30, 2026.
The text of the press release issued by the Company is furnished as Exhibit 99.1 to this report.
The information furnished in this Current Report on Form 8-K under Item 2.02 and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such a filing.
| Item 7.01. | Regulation FD Disclosure. |
The information included in Item 2.02 above is incorporated herein by reference.
The information furnished in this Current Report on Form 8-K under Item 7.01 and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibits: |
Description of Document | |
| 99.1 | Press Release dated July 7, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL, document) | |
2
SIGNATURES
We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.
| Date: July 7, 2026 | ResMed Inc. | |||||
| (registrant) | ||||||
| By: | /s/ Michael J. Rider | |||||
| Name: | Michael J. Rider | |||||
| Its: | Global General Counsel and Secretary | |||||
3
Exhibit 99.1
Resmed Announces Agreement to Sell MatrixCare Business
Sharpens Resmed’s focus on high-growth sleep and connected care markets
SAN DIEGO, July 7, 2026 (GLOBE NEWSWIRE) — Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused exclusively on health care.
This move reflects Resmed’s 2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcare. The divestiture also strengthens Resmed’s ability to reallocate capital and resources toward innovation, operational scale and long-term value creation across its connected, home-based care ecosystem.
MatrixCare provides software solutions to more than 15,000 providers and supports skilled nursing, senior living and long-term care, life planning communities, and home health and hospice care.
“Today’s announcement is about our disciplined approach to portfolio management and our commitment to driving long-term growth,” said Mick Farrell, Chairman and CEO of Resmed. “By focusing on areas where we see the greatest opportunity for sleep health innovation and impact, we are strengthening our ability to deliver life-changing health technologies, improve patient outcomes, and create value for our stakeholders. We are confident MatrixCare and its affiliated businesses will continue to support team members and drive growth under new ownership with a dedicated focus on the long-term care market.”
“Frazier has spent several years evaluating the post-acute care technology sector and believes MatrixCare has established itself as a leading platform serving skilled nursing, senior living, and home health and hospice provider,” said Ryan Lucero, General Partner at Frazier Healthcare Partners. “We are thrilled to partner with the MatrixCare team and plan to invest aggressively in product innovation to help providers deliver better outcomes as the post-acute care landscape continues to evolve.”
The transaction includes MatrixCare and related software offerings historically sold under the MatrixCare brand, including Healthcare First, Citus, and home health and hospice solutions (collectively defined as the “MatrixCare business”). It excludes Resmed’s other software businesses, Brightree in the U.S. and MEDIFOX DAN in Germany.
The transaction is expected to close during the first quarter of Resmed’s fiscal year 2027, subject to required regulatory approvals and customary closing conditions. Until closing, MatrixCare will continue to operate as part of Resmed, with no changes to customer service or support.
Resmed is providing additional information regarding this transaction through a Form 8-K furnished with the U.S. Securities and Exchange Commission (SEC). Supplementary materials related to this press release are available on Resmed’s Investor Relations website at investor.resmed.com.
Resmed will provide further updates regarding the financial impact of the transaction in its regulatory filings for the fourth quarter of its fiscal year 2026, consistent with regulatory requirements.
1
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more at Resmed.com and follow @Resmed.
About Frazier Healthcare Partners
Founded in 1991, Frazier Healthcare Partners is a private equity firm focused exclusively on the healthcare industry. Since its inception, Frazier has raised over $11 billion of capital for private funds and co-investment opportunities and has invested in more than 200 companies over 35 years. Frazier has a philosophy of partnering with strong management teams while leveraging its internal operating resources and network to build exceptional companies. Frazier is headquartered in Seattle, WA, with an office in New York City, and invests broadly across the U.S., Canada, and Europe. For more information about Frazier, visit www.frazierhealthcare.com/home.
For Media
Brad Lotterman Brad.Lotterman@resmed.com
news@resmed.com
For Investors
Salli Schwartz Salli.Schwartz@resmed.com
investorrelations@resmed.com
2